BioPact

Executive Summary

BioPact is a San Diego-based private biotechnology company founded in 2018, specializing in intracellular drug delivery using its proprietary MGMR® (Multi-functional Guided Membrane Receptor) platform. MGMR® is a versatile transmembrane delivery vehicle designed to transport biomolecules (such as proteins, nucleic acids, or other therapeutics) directly into cells, protecting the cargo from degradation while preserving cell viability. The technology addresses a critical bottleneck in drug development—the inefficient and often toxic delivery of macromolecular therapeutics—by enabling targeted, non-disruptive intracellular transport. BioPact's approach has broad potential applications across gene therapy, cell therapy, targeted protein therapeutics, and vaccine development. The company is currently in the preclinical stage, with no disclosed funding rounds or public pipeline candidates. However, its platform technology positions it as a potential partner or acquisition target for larger pharmaceutical companies seeking novel delivery solutions. Given the nascent state of its development, BioPact's immediate value relies on proof-of-concept studies and strategic collaborations to advance MGMR® toward clinical validation.

Upcoming Catalysts (preview)

• Q3 2026Publication of in vivo efficacy data for MGMR® platform60% success
• H2 2026Series A funding round or strategic partnership announcement50% success
• Q3 2026Presentation at a major drug delivery conference (e.g., Controlled Release Society)70% success